Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
NEW YORK, May 14, 2010 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index® (Nasdaq:NBI...
- Easy-to-swallow formulation provides important new alternative for patients RESEARCH TRIANGLE PARK, N.C., May 11 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK) announced today that the...
FRAZER, Pa. and PHILADELPHIA, Nov. 26 /PRNewswire-FirstCall/ -- Cephalon, Inc. (NASDAQ:CEPH) and Eurand, Inc. (NASDAQ:EURX) today announced that they have filed a lawsuit in U.S. District Court...
FRAZER, Pa. and PHILADELPHIA, Oct. 21 /PRNewswire-FirstCall/ -- Cephalon, Inc. (NASDAQ:CEPH) and Eurand NV (NASDAQ:EURX) today announced receipt of a Paragraph IV Certification Notice Letter on...
AMSTERDAM, Netherlands, Nov. 12 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based...
MILAN, Italy, Sept. 4 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX), a global specialty pharmaceutical company, announced today that GlaxoSmithKline (NYSE:GSK), working in collaboration...
Eurand Invites Public to Listen to Webcast MILAN, Italy, Aug. 24 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and...
MILAN, Italy and DAYTON, Ohio, Aug. 23 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX), announced today that Cephalon, Inc. (NASDAQ:CEPH) has signed an agreement to acquire Amrix(R) from ECR...
Adjudication Panel Praises Innovative Approaches to Improving Bioavailability of Drugs MILAN, Italy, Aug. 9 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX) and the Controlled Release Society...
AMSTERDAM, Netherlands, Aug. 6 /PRNewswire-FirstCall/ -- Eurand N.V. (NASDAQ:EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
